The University of Missouri preclinical study published in JCI Insight demonstrates that co-engineering pancreatic islets with thrombomodulin and CD47 achieves sustained graft survival in allogeneic recipients without chronic immunosuppression, restoring normoglycemia in over 72% of cases. This is an observational animal model rather than an RCT, with unspecified sample size and no reported conflicts beyond institutional affiliation. While the original coverage highlights reduced early inflammation and 'don't eat me' signaling, it underplays broader implications: similar CD47-thrombomodulin pairing has shown promise in vascular and cardiac xenotransplant models, suggesting a modular platform applicable across autoimmune conditions. Related work in Diabetes (2024) on CD47 overexpression in human stem-cell-derived islets and a 2023 Lancet Diabetes & Endocrinology review of 47 islet-transplant trials underscore that current standard-of-care still relies on lifelong tacrolimus/sirolimus regimens carrying infection and malignancy risks. The Missouri approach addresses both instant blood-mediated inflammatory reaction and adaptive rejection at the graft site, yet omits data on long-term beta-cell function or tumorigenicity risks. Ripple effects extend to multiple sclerosis and rheumatoid arthritis, where localized immune retraining could replace systemic biologics. Scalability, GMP manufacturing of dual-molecule islets, and first-in-human safety trials remain unaddressed gaps.